Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest

Initial search results include only NCI-sponsored clinical trials. To search all trials, click the "REFINE SEARCH" button, scroll down to the Trial ID/Sponsor section and select the "All" check box in the Sponsor of Trial section.

View Content for:
Display:
?
Drug:  motexafin gadolinium
Find trials that include:  Any drugs shown
Trial Status:  Closed
Results 1-25 of 33 for your search:
Start Over
Breast Cancer Screening With MRI in Women Aged 50-75 Years With Extremely Dense Breast Tissue: the DENSE Trial
Phase: Phase IV
Type: Diagnostic, Screening
Status: Enrolling by invitation
Age: 50 to 75
Sponsor: Other
Protocol IDs: UMCU DENSE, ZONMW-200320002-UMCU, Pink Ribbon-10074, BSP-DENSE, DCS-UU-2009-4348, DCS-UU-2014-6859, NCT01315015
Radiation Therapy Plus Gadolinium Texaphyrin in Treating Patients With Brain Metastases
Phase: Phase III
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: CDR0000066627, PCI-P120-9801, MSKCC-00088, UCLA-9808021, NCI-V98-1470, NCT00003563
Phase III Randomized Study of Motexafin Gadolinium and Whole Brain Radiotherapy Versus Whole Brain Radiotherapy Alone in Patients With Brain Metastases Secondary to Non-Small Cell Lung Cancer
Phase: Phase III
Type: Treatment
Status: Closed
Age: 18 and over
Sponsor: NCI, Pharmaceutical / Industry
Protocol IDs: UCLA-0302038, PCI-P-PCYC-0211, NCT00054795
Phase IB/II Study of Gadolinium Texaphyrin (PCI-0120) Radiosensitization for Palliative Radiotherapy of Brain Metastases (Summary Last Modified 05/98)
Phase: Phase II, Phase I
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: PCI-P120-9501, NCI-V96-0844
Motexafin Gadolinium, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme or Gliosarcoma
Phase: Phase II, Phase I
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: NCI
Protocol IDs: NCI-2009-01092, CDR0000467802, RTOG 0513, U10CA021661, NCT00305864
Study of Weekly Motexafin Gadolinium (MGd) for Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Phase: Phase II, Phase I
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: PCYC-0223, NCT00290004
Phase I/II Trial of Redox Regulation in Patients With Relapsed or Refractory CD20+ NHL
Phase: Phase II, Phase I
Type: Treatment
Status: Closed
Age: 18 and over
Sponsor: Other
Protocol IDs: NU 02H8, 1346001, NU-0228-024, PCI-P-PCYC-0213, NCT00089284
Study of Motexafin Gadolinium for the Treatment of Non-Hodgkin's Lymphoma
Phase: Phase II
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: PCYC-0221, NCT00086034
A Study of Motexafin Gadolinium for the Treatment of Relapsed or Refractory Multiple Myeloma
Phase: Phase II
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: PCYC-0215, NCT00096837
Study of Motexafin Gadolinium (MGd) for Second Line Treatment of Non-Small-Cell Lung Cancer
Phase: Phase II
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: PCYC-0227, NCT00129844
Study of Motexafin Gadolinium for the Treatment of Renal Cell (Kidney) Cancer
Phase: Phase II
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: PCYC-0219, NCT00134186
Motexafin Gadolinium and Radiation Therapy in Treating Young Patients With Pontine Glioma
Phase: Phase II
Type: Treatment
Status: Completed
Age: 21 and under at diagnosis
Sponsor: NCI
Protocol IDs: NCI-2012-01829, CDR0000504107, COG-ACNS0222, ACNS0222, U10CA098543, NCT00387790
Phase I Study of Radiosensitization with Gadolinium Texaphyrin (PCI-0120) in Patients with Advanced Malignancies (Summary Last Modified 07/96)
Phase: Phase I
Type: Treatment
Status: Closed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: PCI-P120-9401, NCI-V96-0841
Phase I Study of Motexafin Gadolinium in Combination With Radiation Therapy in Adults With Newly-Diagnosed Glioblastoma Multiforme
Phase: Phase I
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: NCI
Protocol IDs: UCLA-HSPC-970904203, COOPER-RP-97-126, LAC-USC-6G971, UCD-RW-98-01, UCLA-HSPC-970904201, UCLA-HSPC-970904202, NCI-T97-0108, NCT00003409, T97-0108
Radiation Therapy in Treating Patients With Bile Duct, Gallbladder, or Pancreatic Cancer
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Completed
Age: 18 and over
Sponsor: NCI, Other
Protocol IDs: PCI-97-108, CDR0000066423, NCI-T97-0109, T97-0109, NCT00003411
Radiation Therapy Plus Gadolinium Texaphyrin in Treating Patients With Cancer of the Pancreas That Cannot Be Removed by Surgery
Phase: Phase I
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: NCI, Other
Protocol IDs: CDR0000066941, J9840, P30CA006973, JHOC-98062407, NCI-T97-0115, T97-0115, NCT00003798
Gadolinium Texaphyrin Plus Radiation Therapy in Treating Patients With Supratentorial Glioblastoma Multiforme
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Completed
Age: 18 and over
Sponsor: NCI, Other
Protocol IDs: NABTT-9712 CDR0000066986, P30CA006973, NABTT-9712, JHOC-NABTT-9712, NCT00006452
Motexafin Gadolinium Plus Radiation Therapy in Treating Children With Newly Diagnosed Brain Stem Glioma
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Completed
Age: 21 and under
Sponsor: NCI
Protocol IDs: NCI-2012-01845, COG-A09712, U01CA097452, CDR0000067087, CCG-09712, A09712, NCT00003909
Radiation Therapy and Gadolinium Texaphyrin in Treating Patients With Supratentorial Glioblastoma Multiforme
Phase: Phase I
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: NCI
Protocol IDs: NCI-2012-01400, 99H0239, CDR0000067517, NCI-T99-0041, OSU-9976, OSU-99H0239, U01CA076576, T99-0041, NCT00004262
Chemotherapy, Radiation Therapy, and Surgery in Treating Patients With Stage IIIA Non-small Cell Lung Cancer
Phase: Phase I
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: NCI
Protocol IDs: NCI-2012-01401, OSU 0003, NCI-T99-0073, OSU-99H0355, OSU-T99-0073, CDR0000067669, U01CA076576, T99-0073, NCT00005065
Phase I Study of Motexafin Gadolinium as a Radiosensitizer in Patients With Glioblastoma Multiforme Receiving Cranial Radiotherapy
Phase: Phase I
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: NCI
Protocol IDs: NABTT-2116, JHOC-NABTT-2116, NCT00032097
Start Over